IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes.

Prim Care Diabetes · 2016

Last updated 2026-05-28

IDegLira combines two diabetes medications, insulin degludec and liraglutide, into a single daily injection. This combination aims to improve blood sugar control while reducing side effects like low blood sugar and weight gain compared to other treatments. Clinical data for IDegLira are presented, though specific results are not detailed in the abstract.

AI summary of the abstract below.

Journal	Prim Care Diabetes, 2016
Citations	14
Relative citation ratio	0.69
NIH percentile	38
Molecules	—
Conditions studied	Type 2 Diabetes

Abstract

In type 2 diabetes (T2D), treatment is optimised to minimise hyperglycaemia and the risk of microvascular complications. While there are a number of effective treatments, intensive treatment is associated with negative side effects such as increased hypoglycaemia and weight gain. With complementary modes of action, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and a basal insulin in combination offer an alternative to basal-bolus therapy in T2D. This review describes the rationale behind this treatment combination and presents clinical data available for IDegLira, the first basal insulin (insulin degludec) and GLP-1RA (liraglutide) co-formulation available in one pen for a single injection daily.

Verbatim abstract via PubMed 26776758 ↗